Tobacco use is the leading preventable cause of disease, disability, and death in the US. In 2014, it was estimated that 480 000 deaths annually are attributed to cigarette smoking, including second hand smoke exposure. Smoking during pregnancy can increase the risk of numerous adverse pregnancy...
Library & Search Results
Clinical diagnosis of benign paroxysmal positional vertigo and vestibular neuritis
Not available
Bupropion and Naltrexone in Methamphetamine Use Disorder
BACKGROUND
The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.
METHODS
We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the...
APOE ɛ4 Allele Testing and Risk of Alzheimer Disease
A 64-year-old man presented with concern about an abnormal genetic test result for apolipoprotein E (APOE) obtained through his primary care physician. He reported forgetfulness and word-finding difficulties for 3 years but performed all activities of daily living independently and was...
Behavioral Health Integration Compendium
This Compendium has been developed by the Behavioral Health Integration (BHI) Collaborative, led by several of the nation’s leading physician organizations, as a tool for physicians and their practices to learn about and implement behavioral health integration (BHI) in order to achieve the goal...
Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis
Importance: Mind-body therapies (MBTs) are emerging as potential tools for addressing the opioid crisis. Knowing whether mind-body therapies may benefit patients treated with opioids for acute, procedural, and chronic pain conditions may be useful for prescribers, payers, policy...
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial
Importance: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations.
Objective: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior...